GlassScriptPhysician profile
Mani Ushyarov
NPI 1326000498
$16,505.37
in general payments reported to CMS, 2019-2025
44 companies · $2,008 in 2025
The $2,008 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,318 · 2020: $1,432 · 2021: $2,211 · 2022: $2,127 · 2023: $2,365 · 2024: $3,044 · 2025: $2,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,412 · Education: $5.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,411.68 |
| Education | $5.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,474.70 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $2,451.57 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $1,802.96 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $1,526.21 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Horizon Therapeutics Plc | $788.71 | 2019-2022 | |
| Amgen INC. | $782.68 | 2021-2024 | Repatha, Otezla |
| Amarin Pharma, INC. | $697.88 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $578.20 | 2024-2025 | Zenpep, Vowst |
| Merck Sharp & Dohme LLC | $557.03 | 2019-2024 | Capvaxive |
| Ardelyx, INC. | $472.57 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $458.44 | 2019-2025 | Linzess |
| Pfizer INC. | $404.32 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $347.64 | 2019-2025 | Ztlido |
| Phathom Pharmaceuticals, INC. | $333.65 | 2023-2024 | Voquezna |
| Allergan, INC. | $315.22 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mani Ushyarov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.